Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias

[1]  S. Reisner,et al.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 , 2022, International journal of transgender health.

[2]  Jackie Soo,et al.  Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age , 2022, Obstetrics and gynecology.

[3]  Bethany Samuelson Bannow,et al.  Hormonal therapies and venous thrombosis: Considerations for prevention and management , 2022, Research and practice in thrombosis and haemostasis.

[4]  S. Garzon,et al.  Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review , 2022, Archives of Gynecology and Obstetrics.

[5]  S. Goldhaber,et al.  Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. , 2022, Contemporary clinical trials.

[6]  D. Dimulescu,et al.  Position Paper on the Management of Pregnancy-Associated Superficial Venous Thrombosis. Balkan Working Group for Prevention and Treatment of Venous Thromboembolism , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[7]  J. Hallas,et al.  Does administration of vaginal estrogens increase the risk of venous thromboembolism: A case–control study , 2021, Basic & clinical pharmacology & toxicology.

[8]  Alfredo E Farjat,et al.  Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE , 2021, TH Open.

[9]  P. James.  Women and bleeding disorders: diagnostic challenges. , 2020, Hematology. American Society of Hematology. Education Program.

[10]  O. McCarty,et al.  Heavy menstrual bleeding in women on oral anticoagulants. , 2020, Thrombosis research.

[11]  L. Nayak,et al.  Estrogen and thrombosis: A bench to bedside review. , 2020, Thrombosis research.

[12]  K. Kostev,et al.  Effect of progestogen-only contraception on premenopausal fracture risk: a case-control study , 2020, Osteoporosis International.

[13]  F. Ní Áinle,et al.  VTE risk assessment in pregnancy , 2019, Research and practice in thrombosis and haemostasis.

[14]  L. Sammaritano.  Contraception and preconception counseling in women with autoimmune disease. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[15]  J. Safer,et al.  Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy , 2019, Journal of blood medicine.

[16]  T. Deloughery,et al.  Inappropriate Testing and Treatment of Factor V Leiden and Other Heritable Thrombophilias. , 2019, The American journal of medicine.

[17]  J. Safer,et al.  Cross-Sex Hormones and Acute Cardiovascular Events in Transgender Persons , 2019, Annals of Internal Medicine.

[18]  Dina N. Greene,et al.  Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis. , 2019, Clinical chemistry.

[19]  B. Rochwerg,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. , 2018, Blood advances.

[20]  Tyson Kerr,et al.  Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis , 2018, The Linacre quarterly.

[21]  P. Spritzer,et al.  Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. , 2018, Thrombosis research.

[22]  O. Razum,et al.  Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose. , 2018, Thrombosis research.

[23]  Ashley L. Hodges,et al.  Highlights From the U.S. Selected Practice Recommendations for Contraceptive Use. , 2018, Nursing for women's health.

[24]  J. Manson,et al.  The 2017 hormone therapy position statement of The North American Menopause Society , 2017, Menopause.

[25]  K. Curtis,et al.  Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. , 2017, Contraception.

[26]  T. Deloughery,et al.  Thrombotic issues in transgender medicine: A review , 2017, American journal of hematology.

[27]  R. Fischer-Betz,et al.  EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome , 2015, Annals of the rheumatic diseases.

[28]  M. Pisarska,et al.  Combined hormonal contraception and the risk of venous thromboembolism: a guideline. , 2017, Fertility and sterility.

[29]  K. Curtis,et al.  Progestin-only contraception and thromboembolism: A systematic review. , 2016, Contraception.

[30]  K. Curtis,et al.  Safety of hormonal contraceptives among women with migraine: A systematic review. , 2016, Contraception.

[31]  R. Yousuf,et al.  Cardiovascular Disease Risk Associated With the Long‐term Use of Depot Medroxyprogesterone Acetate , 2016, The American journal of the medical sciences.

[32]  K. Heinemann,et al.  Impact of estrogen type on cardiovascular safety of combined oral contraceptives. , 2016, Contraception.

[33]  S. Kochhar.  UK medical eligibility criteria for contraceptive use , 2016 .

[34]  A. Folsom,et al.  Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. , 2016, Thrombosis research.

[35]  K. Curtis,et al.  U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[36]  Madison,et al.  U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. , 2013, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  L. Kocoska-Maras,et al.  Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration , 2016, Menopause.

[38]  A. Schindler,et al.  Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day , 2016, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[39]  M. Prins,et al.  Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. , 2016, Blood.

[40]  K. Kostev,et al.  The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK , 2016, Osteoporosis International.

[41]  Leo Han,et al.  Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk? , 2015, Obstetrics and gynecology clinics of North America.

[42]  V. Montori,et al.  Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[43]  Hadine Joffe,et al.  Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society , 2015, Menopause.

[44]  T. Stijnen,et al.  Combined oral contraceptives: venous thrombosis. , 2014, The Cochrane database of systematic reviews.

[45]  A. V. D. Van Der Zee,et al.  The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. , 2013, American journal of obstetrics and gynecology.

[46]  A. Burke,et al.  Obesity and Hormonal Contraceptive Efficacy , 2013, Women's health.

[47]  J. Horsman,et al.  Bleeding disorders, menorrhagia and iron deficiency: impacts on health‐related quality of life , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  R. Ferriani,et al.  Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial. , 2012, Thrombosis research.

[49]  N. Terrin,et al.  Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis , 2012, BMJ : British Medical Journal.

[50]  K. Curtis,et al.  Contraception for individuals with sickle cell disease: a systematic review of the literature. , 2012, Contraception.

[51]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[52]  F. Rosendaal,et al.  Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study , 2008, Journal of thrombosis and haemostasis : JTH.

[53]  P. Čičovački.  SOCIETY , 2008, Society.

[54]  S. le Cessie,et al.  Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations , 2007, British journal of haematology.

[55]  R. Lobo,et al.  Formation of ethinyl estradiol in women during treatment with norethindrone acetate. , 2007, The Journal of clinical endocrinology and metabolism.

[56]  P. Miller,et al.  Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. , 2006, Contraception.

[57]  R. Langer,et al.  Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus , 2006, Archives of internal medicine.

[58]  R. Sitruk-Ware.  New progestagens for contraceptive use. , 2006, Human reproduction update.

[59]  I. Wiegratz,et al.  Metabolic and clinical effects of progestogens , 2006, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[60]  H Kuhl,et al.  Pharmacology of estrogens and progestogens: influence of different routes of administration , 2005, Climacteric : the journal of the International Menopause Society.

[61]  A. Algra,et al.  Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. , 2004, Blood.

[62]  J. Bélaisch.  [Contraception during the perimenopause]. , 2003, Presse medicale.

[63]  F. Rosendaal,et al.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.

[64]  D. Margolis,et al.  Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. , 2001, Contraception.

[65]  J. Guillebaud,et al.  Medical eligibility criteria for contraceptive use , 2018, Advanced Health Assessment of Women.

[66]  M. Soules,et al.  Executive summary: Stages of Reproductive Aging Workshop (STRAW) , 2001, Climacteric : the journal of the International Menopause Society.

[67]  F. Howard,et al.  Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[68]  C. Farquhar,et al.  Antifibrinolytics for heavy menstrual bleeding. , 2000, The Cochrane database of systematic reviews.

[69]  H. C. Coelingh Bennink,et al.  A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. , 1998, Contraception.

[70]  Z. de Castillo,et al.  Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. , 1997, Contraception.

[71]  G. Serjeant,et al.  MEDROXYPROGESTERONE ACETATE AND HOMOZYGOUS SICKLE-CELL DISEASE , 1982, The Lancet.